Sanara MedTech Inc. (SMTI)

Kritische 8-K Meldungen

DatumMeldungSchwereFilingAuszug
23.05.2025Item 5.02 — Abgang SchlüsselpersonenHOCHSEC            Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers

Stammdaten

Sanara MedTech Inc. develops, markets, and distributes wound and skin care products to physicians, hospitals, clinics, and post-acute care settings in the United States. It offers CellerateRX Surgical Activated Collagen powder and gel that are used in a range of surgical specialties to help promote patient healing; Biako's Antimicrobial Skin and Wound Cleanser, a patented product that disrupts extracellular polymeric substances to eradicate mature biofilm microbes; Biako's Antimicrobial Wound Gel, an antimicrobial hydrogel wound dressing helps against planktonic microbes, as well as immature and mature biofilms; and Biako's Antimicrobial Skin and Wound Irrigation Solution. The company also provides HYCOL Hydrolyzed Collagen Powder and Gel, a medical hydrolysate of Type I bovine collagen for the management of full and partial thickness wounds, including pressure ulcers, venous and arterial leg ulcers, and diabetic foot ulcers. In addition, it develops FORTIFY TRG, a freeze-dried, multi-layer small intestinal submucosa extracellular matrix sheet; FORTIFY FLOWABLE extracellular matrix, an advanced wound care device; and VIM Amnion Matrix, a single layer sheet of amnion tissue. The company was formerly known as WNDM Medical Inc. and changed its name to Sanara MedTech Inc. in May 2019. Sanara MedTech Inc. was incorporated in 2001 and is based in Fort Worth, Texas.

Unternehmen & Branche

NameSanara MedTech Inc.
TickerSMTI
CIK0000714256
BoerseUS
SektorHealthcare
IndustrieMedical - Instruments & Supplies
SIC3842 · Orthopedic, Prosthetic & Surgical Appliances & Supplies

Wertpapier & Kennzahlen

CUSIP
ISIN
TypCommon Stock
Marktkapitalisierung167,4 Mio. USD
Beta1,10
Dividendenrendite0,00 %

Externe Quellen: SEC EDGAR » · FMP-Profil » · Yahoo Finance »

Finanzkennzahlen (SEC XBRL)

PeriodeFilingUmsatzNettoergebnisEPSAktivaEigenkapital
2025-12-3110-K103,117,982-37,562,606-4.3672,944,0715,938,442
2025-09-3010-Q26,333,819-30,411,153-3.4071,088,6486,148,956
2025-06-3010-Q25,830,834-2,014,362-0.2398,767,64535,399,413
2025-03-3110-Q23,434,096-3,527,177-0.4196,378,58136,671,008
2024-12-3110-K86,672,425-9,664,547-1.1488,091,99239,403,573
2024-09-3010-Q21,671,599-2,857,768-0.3488,545,47639,783,866
2024-06-3010-Q20,158,823-3,504,014-0.4173,383,60541,706,302
2024-03-3110-Q18,536,638-1,764,184-0.2170,911,94043,290,685
2023-12-3110-K64,989,842-4,303,197-0.5273,871,14944,832,277
2023-09-3010-Q16,024,948-1,060,370-0.1373,871,14944,316,800
2023-06-3010-Q15,753,164-1,827,733-0.2273,871,14941,148,929
2023-03-3110-Q15,521,917-1,177,900-0.1459,967,35441,624,754
2022-12-3110-K45,842,845-7,937,497-1.0061,035,38641,827,530
2022-09-3010-Q13,044,571-1,470,460-0.1861,477,39045,457,988
2022-06-3010-Q9,670,778769,4260.0946,477,70736,198,369
2022-03-3110-Q7,811,223-3,129,32433,933,72029,031,264
2021-12-3110-K24,143,919-7,921,91436,396,43130,640,401
2021-09-3010-Q5,823,942-2,047,86137,927,93433,422,632
2021-06-3010-Q6,277,133-1,205,97338,784,66034,657,463
2021-03-3110-Q11,286,569-1,183,37639,018,00935,471,635

Fondsaktivität (Vorquartalsvergleich)

Keine Fondsdaten für dieses Unternehmen vorhanden.

Insider-Transaktionen (12 Monate)

Keine Insider-Käufe/Verkäufe in den letzten 12 Monaten.

Top-Fondshalter

Keine Fondsdaten zu dieser Aktie vorhanden.

Hinweis

Erweitert ×